ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ANAB AnaptysBio Inc

22.52
1.14 (5.33%)
Mar 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 470,804
Bid Price 15.00
Ask Price 23.45
News -
Day High 22.87

Low
13.36

52 Week Range

High
27.50

Day Low 20.815
Company Name Stock Ticker Symbol Market Type
AnaptysBio Inc ANAB NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
1.14 5.33% 22.52 16:30:00
Open Price Low Price High Price Close Price Prev Close
21.47 20.815 22.87 22.52 21.38
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
7,773 470,804 $ 21.89 $ 10,305,366 - 13.36 - 27.50
Last Trade Time Type Quantity Stock Price Currency
16:17:51 47 $ 20.93 USD

AnaptysBio Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
601.63M 26.76M - 10.29M -128.72M -4.81 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

AnaptysBio News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ANAB Message Board. Create One! See More Posts on ANAB Message Board See More Message Board Posts

Historical ANAB Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week24.3424.7320.6421.97463,183-1.82-7.48%
1 Month26.2327.0020.6423.59387,647-3.71-14.14%
3 Months21.2927.5020.6423.70305,0661.235.78%
6 Months18.4727.5013.3620.80266,7014.0521.93%
1 Year21.8527.5013.3620.28253,1300.673.07%
3 Years20.8437.8913.3623.71242,7731.688.06%
5 Years67.5683.109.1624.15325,524-45.04-66.67%

AnaptysBio Description

AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from the collaborative research and development arrangements.

Your Recent History

Delayed Upgrade Clock